Venture Life Share Price (VLG)

"Dear Sir or Madam,

Last year in your RNS of 16th November, concerning the trial of Dentyl's effectiveness against Covid-19, you stated: "The Company looks forward to concluding the human (in-vivo) clinical study in partnership with Cardiff University and will update the market with the results in early 2021, once published."

In your half year report in September you stated "The in-vivo study at Cardiff University on Dentyl completed in April 2021 and is under peer-review and we await the results which we expect to be published shortly."

Given the enormous possible importance of this trial with regard to the whole Covid-19 pandemic and the many, many, lives being lost and traumatized, as a long term investor may I ask the reason for this very long delay. You yourselves originally expected it to be finished, peer reviewed and published in "early 2021" and in this instance it is no small matter.

If the trial had a negative result that is still important news and may affect people's behaviour, and also directions for further research into the nature of the disease, and having published the results of the in-vitro trial (through a dedicated RNS) and then undertaken the in-vivo trial surely you do have an obligation to update the public of your results.

It is also price sensitive information that I would expect cannot be legally withheld.

At least as a minimum could you indicate an actual date by which we can expect these results.

etc"

tks for the advice

@jollyspeculator: Blatant de-ramp with no basis, as you probably have a sell position open.

Company is in a strong financial position with little percentage debt so take your agenda elsewhere.

It’s going up Stonehage Fleming adding to holding

"Venture Life (-25.9%) was the standout disappointment in the month,
with management disclosing further margin headwinds despite only releasing a trading statement
the prior month. As the business grows organically and with the additions of the recent acquisitions
and a relatively fixed manufacturing overhead, margins and earnings should improve. "

https://www.downing.co.uk/investor/offers/downing-strategic-micro-cap-investment-trust